SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Ziopharm Oncology Inc – ‘8-K’ for 5/11/15

On:  Friday, 5/15/15, at 4:15pm ET   ·   For:  5/11/15   ·   Accession #:  1193125-15-190221   ·   File #:  1-33038

Previous ‘8-K’:  ‘8-K’ on / for 5/7/15   ·   Next:  ‘8-K’ on 6/2/15 for 6/1/15   ·   Latest:  ‘8-K’ on 2/22/24 for 2/15/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 5/15/15  Ziopharm Oncology Inc             8-K:5,9     5/11/15    2:19K                                    RR Donnelley/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     15K 
 2: EX-17.1     Letter re: Departure of Director                    HTML      4K 


8-K   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



  Form 8-K  

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 11, 2015

 

 

ZIOPHARM Oncology, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-33038   84-1475672

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

One First Avenue, Parris Building 34, Navy Yard Plaza

Boston, Massachusetts

  02129
(Address of Principal Executive Offices)   (Zip Code)

(617) 259-1970

(Registrant’s telephone number, including area code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

 

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Decision to Resign and Not Stand for Reelection

On May 11, 2015, Jonathan Lewis, M.D., Ph.D. notified ZIOPHARM Oncology, Inc., or the Company, of his decision to resign effective immediately and not to stand for re-election at the Company’s 2015 Annual Meeting of Stockholders, or the Annual Meeting. Dr. Lewis’ decision to resign and not to stand for re-election was not a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices, or other occurrence that would require disclosure under Item 5.02(a) of Form 8-K. A copy of Dr. Lewis’ resignation email is filed as Exhibit 17.1 to this Current Report on Form 8-K and is incorporated herein by reference.

As a result of Dr. Lewis’ resignation, there is now one vacancy on the Company’s board of directors. The Company’s board of directors has determined not to nominate a new nominee for election at the Annual Meeting to fill the vacancy created by Dr. Lewis’ resignation.

 

Item 9.01 Financial Statements and Exhibits

 

  (d) Exhibits

 

Exhibit
No.

  

Description

17.1    Email from Jonathan Lewis, M.D., Ph.D. to the board of directors of ZIOPHARM Oncology, Inc., dated May 11, 2015


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

ZIOPHARM Oncology, Inc.
By:

/s/ Kevin G. Lafond

Date: May 15, 2015 Name: Kevin G. Lafond
Title: Vice President, Chief Accounting Officer and Treasurer


INDEX OF EXHIBITS

 

Exhibit
No.

  

Description

17.1    Email from Jonathan Lewis, M.D., Ph.D. to the board of directors of ZIOPHARM Oncology, Inc., dated May 11, 2015

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on:5/15/15SC 13G/A
For Period End:5/11/15
 List all Filings 
Top
Filing Submission 0001193125-15-190221   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 5:53:07.1am ET